uMed is sponsoring the inaugural GBA1 meeting taking place in Montreal at the end of June 2024. The meeting is focused on all aspects of GBA1 research and serves as a platform to collectively advance the understanding and treatment of GBA1-associated neurodegenerative diseases.
Mutation in the GBA1 gene has emerged as one of the most common genetic abnormalities associated with Parkinson’s Disease, with approximately 5-10% of PD patients carrying a GBA1 mutation in comparison to <1% of the healthy population. This meeting aims to accelerate research and treatment for neurodegeneration related to GBA1, generating models, research tools, data, and additional resources all focused on GBA1 to share with the scientific community and industry.
The meeting will be held at the ‘The Neuro’ at McGill University in Montreal, Canada, and invites health professionals and stakeholders from academia and industry with an interest in GBA1 research.
uMed will also be presenting a poster – ‘Remote DNA Collection for Parkinson’s Research: Insights from AccessPD’ – on Thursday June 27th from 12.15, poster #6. The abstract outlines our experiences with remotely collecting DNA samples to analyze genetic variants and risk factors associated with PD.
Visit the event website for more information and to register for tickets.
How uMed’s AccessPD Cohort is building a complete patient picture with access to custom data and insights.
AccessPD is a unique patient cohort that combines the collection of genetic samples from PD patients at home with routinely collected EMR and additional outcomes, including wearable device data and clinically validated scales. This provides researchers with access to a rich source of regulatory grade data which can then be augmented with the collection of custom genetic samples and data as required to answer specific research questions.
Furthermore, AccessPD enables the running of standalone studies within the infrastructure of the existing cohort, reducing the need to recruit from scratch, therefore significantly reducing costs and accelerating research timelines.
Find out more about AccessPD here. If you are attending GBA1 and would like to discuss how AccessPD can support your research goals, please contact us at hello@umed.io to set-up a meeting at the event.
Parkinson’s Research Roundtable – 27th June
Parkinson’s Remote Outcome Measure Testbed (PROMT)
Using a platform registry model to evaluate novel digital endpoints/outcome measures for clinical trials and post-approval evidence creation.
uMed will be hosting a Research Roundtable on the first evening of the GBA1 Conference (June 27th).
This roundtable aims to obtain input from leading Parkinson’s researchers, drug manufacturers, digital device manufacturers and patient groups as the basis for a future proposal that can be presented to funders to enable the evaluation of multiple digital & novel endpoints through the AccessPD platform for use in upcoming Parkinson’s clinical trials.
Discussion points will include:
- The identification of the most valuable endpoints to advance PD research
- The potential of digital endpoints over existing scales
- The requirement for new PRO scales, if any
- What patient and/or caregiver preference data would be useful to track
- Stages of disease progression as a focus for the evaluation of digital endpoints
The roundtable is a closed event and by invitation only. If you are interested to find out more or attend please contact us at hello@umed.io.
